← Back to patent-cliff list
OATD-01
Tier C — Watch / tradeOATD-01
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AMCase, CHIT1
Indications (approved)：Non-alcoholic steatohepatitis, Interstitial lung disease, Sarcoidosis, Idiopathic pulmonary fibrosis, 肺结节病, Asthma
Regional status
US
Phase II
2024-03-21
EU
Phase II
2024-03-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of OATD-01?
Approved indications include: Non-alcoholic steatohepatitis, Interstitial lung disease, Sarcoidosis, Idiopathic pulmonary fibrosis, 肺结节病, Asthma.
When does the OATD-01 patent expire?
No public expiry year is available for OATD-01 yet; this page updates once verified.
How do I get a quote for OATD-01 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01